NSW has rewritten the rules for cosmetic injectables, and the commercial weight of it lands on brands and distributors as much as on clinics

On 5 November, New South Wales replaced the medicines framework that had governed the state for roughly sixty years. The Medicines, Poisons and Therapeutic Goods Act 2022 and the Medicines, Poisons and Therapeutic Goods Regulation 2026 commenced together, retiring the Poisons and Therapeutic Goods Act 1966 and its 2008 Regulation. Across most of the economy that change reads as administrative housekeeping, a tidying up of language and numbering that nobody outside a compliance team will ever notice. In aesthetics it is a different proposition entirely, because Part 9 of the new Regulation creates a dedicated framework for what NSW calls cosmetic use substances, and it turns many things the industry has long described as best practice into enforceable legal obligations, backed by a new tiered penalty regime.

The substances in scope are Schedule 4 (prescription only) medicines used for cosmetic purposes: botulinum toxins, deoxycholic acid, and dermal fillers including calcium hydroxylapatite, collagen, hyaluronic acid and its polymers, polyacrylamide, polycaprolactone and polylactic acid. If a clinic uses any of these for a cosmetic purpose, Part 9 applies to it. The fact that the purpose is cosmetic rather than therapeutic removes none of the obligations that attach to a prescription medicine. That framing matters more than it sounds, because a sizeable part of our industry has been managing injectable stock with the same mental model it uses for retail inventory, and a fundamental point for clinic owners is that cosmetic use does not turn a prescription medicine into an ordinary beauty product, which means injectable medicine management now belongs inside a healthcare compliance system rather than ordinary salon stock management.

Only medical practitioners and nurse practitioners may prescribe or issue a direction to administer these substances, and designated registered nurse prescribers cannot issue directions for cosmetic use substances. Before prescribing or issuing a written direction, the prescriber must review the patient in person or by video consultation, which means a questionnaire, photo upload or asynchronous chat does not meet this standard, and verbal directions are allowed only if the prescriber is physically present when the substance is administered. Written directions are valid for six months and signed by the prescriber, and must include the patient's name and address, prescriber details and contact information, administration address, the responsible provider's name, the date of review, the validity period, and the dosing frequency, and for each substance, the name and form, the area of face or body, the route (if not obvious), and the quantity.

Nurses may administer only if acting within nursing practice and either directed by a prescriber or administering a substance lawfully prescribed and dispensed for the patient, and no other person may administer these products. Nurses must ensure emergency equipment is available, confirm the product's lawful status, and keep a written record of each administration including the batch number, patient details, and the prescriber and treatment details. That brings us to the word clinic owners should sit with, which is responsible provider, because it is the Regulation's name for the business behind the treatment and owners are the responsible provider and carry direct legal responsibility alongside the nurses and prescribers working in the clinic. Responsible providers must keep copies of all directions and administration records for two years, make them available for inspection on demand, and maintain appropriate risk management policies and procedures, keep appropriate emergency equipment available at all times, and ensure nurses administering substances are trained to respond to medical emergencies. Storage must be in a non-public area, separate from food, protected against contamination if containers break or leak, and according to label instructions.

The penalties are structured in two categories. Category 1 covers the core safety and authority conditions: administration only under a valid direction or lawful prescription using legitimately supplied products, emergency equipment availability, the prescriber's personal review of the patient, and the responsible provider's risk management policies and emergency training, with maximum penalties of 200 penalty units or 6 months' imprisonment for an individual, and 1,000 penalty units for a corporation. Category 2 covers the content of directions, keeping records and copies, and storing substances correctly, with maximums of 50 penalty units for an individual and 250 for a corporation, and some Category 2 breaches may also attract on-the-spot penalty notices. Across the Act's five tiers, penalties range from 20 to 400 penalty units for individuals and 100 to 2,000 penalty units for corporations, which at $110 per unit works out at roughly $2,200 to $44,000 for individuals and $11,000 to $220,000 for bodies corporate.

One proposal from the consultation draft did not survive into the final Regulation, and that was the tighter restriction on drawing doses for more than one patient from a single vial. Nobody should read its absence as permission, because batch-level records, labelling, sterility and TGA manufacturing rules on compounding still apply, and NSW Health has said it aims to stop compounding of cosmetic injectables without an appropriate TGA manufacturing licence, including preparing multiple doses from one vial. Multi-patient vial practices should be checked against product instructions and TGA requirements rather than against the fact that one proposed clause was dropped.

For brands and distributors, the sharpest line in Part 9 is the one about lawful supply, because a doctor or nurse practitioner may prescribe or direct administration only if the product is on the ARTG, approved under section 19 or 19A of the Commonwealth Therapeutic Goods Act 1989, or supplied by a TGA-licensed manufacturer, and the administering nurse must also confirm this before injecting. NSW Health aims to remove illegally imported, unregistered and unregulated products, and has specifically identified illegally imported cosmetic products as a patient-safety concern. If you sell into NSW clinics, you should expect your account managers to be asked for documentation they have never been asked for before, and you should expect your clinical education content to be read as a compliance asset rather than a nice-to-have. The brands that come out of this period in better shape will be the ones that can hand a clinic owner a clean supply pathway, a batch traceability answer, and training material that maps to the new obligations, while the ones who struggle will be the ones whose answer to a sourcing question has always been a phone call rather than a document.

It is worth being clear that this is a state framework rather than a national one, which creates a real problem for any brand producing one set of national materials. Queensland permits telehealth prescribing after consultation, but only a physically present doctor or nurse practitioner with exclusive custody may hold clinic stock, and registered nurses cannot hold stock, so nurse-led clinics without an onsite prescriber rely on patient-specific dispensing. Victoria runs a traditional prescribe-and-administer model under general drugs and poisons law, with prescriptions lasting up to 12 months. Western Australia requires a Health Service Permit to purchase and store Schedule 4 medicines at a cosmetic clinic, issued only to a doctor or nurse practitioner, with registered nurses administering only after consultation with and under the direction of the authorising practitioner. South Australia, Tasmania, the ACT and the Northern Territory continue under general drugs and poisons frameworks with no dedicated cosmetic regime. The common thread is regulatory focus on who controls stock, and remote prescribers ordering product for clinics they never attend are under scrutiny.

The last piece sits on top of everything above. The advertising layer has been tightening for more than a year, with AHPRA's guidelines for registered health practitioners who perform non-surgical cosmetic procedures and for advertising higher risk non-surgical cosmetic procedures both effective from 2 September 2025, and the TGA's June 2026 updated guidance on prescription medicine advertising making clear the ambit of the restrictions now facing clinics, particularly where public-facing content refers directly or indirectly to cosmetic injectables, GLP-1 receptor agonists, peptides or other prescription-only products. Regulators reviewing NSW clinics will look at websites and social media alongside records, and the gap between what a clinic promises publicly and what its documentation can support is exactly where a compliance problem becomes a commercial one.

What we would do this week, if we were advising a clinic, is sit down with the booking and consultation flow first, because the in-person or video review requirement is the change most likely to be breached by a process that was designed for convenience and has never been revisited since. After that, the record keeping, since the two-year retention and inspection-on-demand obligations fall on the business rather than on the individual practitioner, and most clinics have no system that produces an auditable trail on request. If you are a brand reading this, the work is different but no less urgent, and it starts with being able to evidence your own supply pathway and ending any arrangement in your distribution chain that you would not want examined. Our industry has spent a long time arguing about whether aesthetics is beauty or healthcare, and NSW has now answered that question in legislation. The businesses that adjust their systems to the answer will be the ones still trading comfortably on the other side of it.

This is general information rather than legal advice, and clinics should refer to the Medicines, Poisons and Therapeutic Goods Act 2022 and the Medicines, Poisons and Therapeutic Goods Regulation 2026, or take their own advice, for how the requirements apply to them.